BC Week In Review | Feb 10, 2017
Clinical News

Alidornase alfa: Interim Ph II data

Interim data from an open-label, Israeli Phase II trial in 13 evaluable CF patients previously treated with Pulmozyme dornase alfa showed that once-daily 2.5 mg inhaled alidornase alfa for 28 days led to a 4.1...
BC Week In Review | Dec 30, 2016
Clinical News

AIR DNase: Completed Ph II enrollment

Protalix completed enrollment of 15 patients switching over from Pulmozyme dornase alfa in an open-label, Israeli Phase II trial evaluating 2.5 mg inhaled AIR DNase once daily for 28 days. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel...
BC Week In Review | Jul 18, 2016
Clinical News

AIR DNase: Phase II started

Protalix began an open-label, Israeli Phase II trial to evaluate 2.5 mg inhaled AIR DNase once daily for 28 days in 15 patients switching over from Pulmozyme dornase alfa. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX),...
BioCentury | Apr 27, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/24 cls Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Canaccord Corey Davis Downgrade Hold (from buy) -62% $12.87 Needham Serge Belanger Downgrade Hold...
BC Week In Review | Jul 22, 2013
Clinical News

Protalix preclinical data

Protalix said PRX-110 showed improved enzyme kinetics, less sensitivity to inhibition by actin and improved ex vivo efficacy in sputum from CF patients vs. Pulmozyme dornase alfa. The company plans to submit an IND to...
Items per page:
1 - 5 of 5